Grail Inc (GRAL)

Currency in USD
99.25
-5.59(-5.33%)
Closed·
103.49+4.24(+4.27%)
·
Advertisement
GRAL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
98.36103.96
52 wk Range
41.50166.47
Key Statistics
Prev. Close
104.84
Open
100.93
Day's Range
98.36-103.96
52 wk Range
41.5-166.47
Volume
758K
Average Volume (3m)
1.04M
1-Year Change
6.093%
Book Value / Share
54.93
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GRAL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
139.44
Upside
+40.50%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Grail Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

5 Buy
5 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 139.44
(+40.50% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Hold130.00+30.98%74.00Maintain10/11/2026
Mizuho
Hold110.00+10.83%100.00Maintain06/11/2026
TD Cowen
Buy175.00+76.32%180.00Maintain05/11/2026
RBC Capital
Hold100.00+0.76%84.00Maintain05/11/2026
Baird
Buy150.00+51.13%155.00Maintain05/11/2026

Grail Inc Earnings Call Summary for Q2/2026

  • GRAIL Q2 revenue hit $44.7M, beating estimates by 3.5% with 26% YoY growth; test volume surged 35% to 61,000 tests driven by screening sales.
  • Shares dropped 8.33% after-hours despite revenue beat as adjusted EBITDA loss widened to $90.3M from $78.4M YoY; net loss remained $110.2M.
  • Company expects FDA advisory committee meeting fall 2026 with potential approval in early 2027, viewed as critical catalyst for payer coverage.
  • Cash position stands at $861.6M including $110M Samsung investment; Illumina 7% royalty resumes Q4 2026, potentially impacting 2027 margins.
  • Management expanded sales force ahead of FDA decision; average test price fell to ~$700 due to strategic mix shift toward digital health partnerships.
Last Updated: 05/08/2026, 22:32
Read Full Transcript

Earnings

Latest Release
04/11/2026
EPS / Forecast
-2.21 / --
Revenue / Forecast
37.5M / 45.3M
EPS Revisions
Last 90 days

Grail (GRAL) Income Statement & Profits

Compare GRAL to Peers and Sector

Metrics to compare
GRAL
Peers
Sector
Relationship
P/E Ratio
−11.0x−13.0x−0.2x
PEG Ratio
−0.54−0.010.00
Price/Book
1.8x1.7x2.6x
Price / LTM Sales
26.8x15.4x2.6x
Upside (Analyst Target)
40.5%29.4%77.0%
Fair Value Upside
Unlock−29.8%13.7%Unlock

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Sunnyvale, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
12.58M27.98%1.25B
Other Institutional Investors
29.22M64.99%2.90B
Public Companies & Retail Investors
3.16M7.04%313.94M
Total
44.96M100.00%4.46B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Farallon Capital Management, L.L.C.9.05%4,069,233403,871
Baker Bros. Advisors LP8.96%4,028,614399,840

People Also Watch

103.32
TWST
-7.44%
94.38
GLW
-10.94%
99.86
CRDO
-15.20%
88.91
ANT
-8.50%
187.22
COHR
-12.90%

FAQ

What Is the Grail (NASDAQ: GRAL) Share Price Today?

The Grail stock price today is 99.25 USD.

What Stock Exchange Does Grail (GRAL) Trade On?

Grail is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Grail?

The stock symbol (also called a 'ticker') for Grail is "GRAL."

What Is the Current Grail Market Capitalisation?

As of today, Grail (NASDAQ: GRAL) market cap is 4.46B USD.

What Is Grail's (GRAL) Earnings Per Share (TTM)?

The Grail EPS is currently -9.27 (Trailing Twelve Months).

Is GRAL a Buy or Sell From a Technical Analyst Perspective?

Based on today's Grail moving averages and other technical indicators, the daily buy/sell signal for GRAL stock is Strong Sell.

How Many Times Has Grail Stock Split?

Grail has split 0 times. (See the GRAL stock split history page for full effective split date and price information.)

How Many Employees Does Grail Have?

Grail has 910 employees, based on their latest Companies House report.

What is the current trading status of Grail (NASDAQ: GRAL)?

As of 22/11/2026, Grail (GRAL) is trading at a share price of 99.25 USD, with a previous close of 104.84 USD. The stock has fluctuated within a day range of 98.36 USD to 103.96 USD, while its 52-week range spans from 41.50 USD to 166.47 USD.

What Is Grail (GRAL) Price Target According to Analysts?

The average 12-month price target for Grail is 139.44 USD, with a high estimate of 175 USD and a low estimate of 100 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +40.50% Upside potential.

What Is the GRAL Premarket Price?

GRAL's last pre-market stock price is 100.17 USD. The pre-market share volume is 2,160.00, and the stock has decreased by -4.67, or -4.45%.

What Is the GRAL After Hours Price?

GRAL's last after hours stock price is 103.49 USD, the stock has decreased by 4.24, or 4.27%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.